Soros Fund Management LLC Invests $4.84 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Soros Fund Management LLC purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 120,373 shares of the company's stock, valued at approximately $4,843,000. Soros Fund Management LLC owned approximately 0.19% of Kymera Therapeutics at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after buying an additional 270 shares in the last quarter. KBC Group NV grew its holdings in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after purchasing an additional 2,350 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Kymera Therapeutics during the fourth quarter valued at $251,000.

Insider Buying and Selling at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on KYMR shares. Stephens reaffirmed an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Citigroup began coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $56.36.

Kymera Therapeutics Stock Up 2.1 %

Shares of Kymera Therapeutics stock traded up $0.73 on Friday, reaching $35.28. The stock had a trading volume of 640,377 shares, compared to its average volume of 556,530. Kymera Therapeutics, Inc. has a 1 year low of $19.45 and a 1 year high of $53.27. The company has a 50 day moving average price of $29.68 and a 200 day moving average price of $38.18. The stock has a market capitalization of $2.29 billion, a P/E ratio of -15.08 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. On average, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.